Percent changes after fenofibrate intervention in medium TG subgroup versus lipoprotein cluster 2.

High Density Lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy

Yetukuri, Laxman
Huopaniemi, I.
Koivuniemi, Artturi
Maranghi, M.
Hiukka, A.
Nygren, Heli
Kaski, S.
Taskinen, M.-R.
Vattulainen, I.
Jauhiainen, M.
Orešič, Matej

January 2011

In a recent FIELD study the fenofibrate therapy surprisingly failed to achieve significant benefit o...

Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study

Ansquer, Jean-Claude
Corda, Christophe
Le Malicot, Karine
Jessent, Valerie

April 2009

AbstractBackground: Elevated plasma low-density lipoprotein cholesterol (LDL-C) concentrations are h...

High Density Lipoprotein Structural Changes and Drug Response in Lipidomic Profiles following the Long-Term Fenofibrate Therapy in the FIELD Substudy

Laxman Yetukuri
Ilkka Huopaniemi
Artturi Koivuniemi
Marianna Maranghi
Anne Hiukka
Samuel Kaski
Marja-riitta Taskinen
Ilpo Vattulainen
Matti Jauhiainen

August 2016

In a recent FIELD study the fenofibrate therapy surprisingly failed to achieve significant benefit o...

Percent changes after fenofibrate intervention in high TG subgroup versus lipoprotein cluster 3.

Kees van Bochove (158872)
Daniël B. van Schalkwijk (158880)
Laurence D. Parnell (158888)
Chao-Qiang Lai (158896)
José M. Ordovás (5648779)
Albert A. de Graaf (158909)
Ben van Ommen (47414)
Donna K. Arnett (123469)

June 2012

†indicates significantly different with respect to cluster 3 and high TG subgroup, p<0.01.‡<p...

Percent changes after fenofibrate intervention in low HDLc subgroup versus subjects in lipoprotein clusters 2 and 3.

Kees van Bochove (158872)
Daniël B. van Schalkwijk (158880)
Laurence D. Parnell (158888)
Chao-Qiang Lai (158896)
José M. Ordovás (5648779)
Albert A. de Graaf (158909)
Ben van Ommen (47414)
Donna K. Arnett (123469)

June 2012

†indicates significantly different with respect to cluster 2/3 and not low HDL subgroup, p<0.01.<...

Percent changes after fenofibrate intervention, grouped by NMR clustering.

Kees van Bochove (158872)
Daniël B. van Schalkwijk (158880)
Laurence D. Parnell (158888)
Chao-Qiang Lai (158896)
José M. Ordovás (5648779)
Albert A. de Graaf (158909)
Ben van Ommen (47414)
Donna K. Arnett (123469)

June 2012

†indicates significantly different with respect to cluster 1, p<0.01.‡indicates significan...

Clustering by Plasma Lipoprotein profile reveals two distinct subgroups with positive lipid response to Fenofibrate therapy

Bochove, K. van
Schalkwijk, D.B. van
Parnell, L.D.
Lai, C.Q.
Ordovás, J.M.
Graaf, A.A. de
Ommen, B. van
Arnett, D.K.

January 2012

Fibrates lower triglycerides and raise HDL cholesterol in dyslipidemic patients, but show heterogene...

Clustering by Plasma Lipoprotein Profile Reveals Two Distinct Subgroups with Positive Lipid Response to Fenofibrate Therapy

Kees Van Bochove
Daniël B. Van Schalkwijk
Laurence D. Parnell
Chao-qiang Lai

August 2016

Fibrates lower triglycerides and raise HDL cholesterol in dyslipidemic patients, but show heterogene...

Baseline characteristics of subjects in clustering on lipoprotein profile.

Kees van Bochove (158872)
Daniël B. van Schalkwijk (158880)
Laurence D. Parnell (158888)
Chao-Qiang Lai (158896)
José M. Ordovás (5648779)
Albert A. de Graaf (158909)
Ben van Ommen (47414)
Donna K. Arnett (123469)

June 2012

†indicates significantly different with respect to cluster 1, p<0.01.‡indicates significan...

702 Fenofibrate and LDL Metabolic Heterogeneity in Hypercholesterolemia

October 2016

Metabolic heterogeneity in low density lipoprotein (LDL) may be detected by examination of the daily...

Paradoxical decrease in high density lipoprotein cholesterol with fenofibrate : a quite rare phenomenon indeed

G. Mombelli
F. Pazzucconi
A. Bondioli
A. Zanaboni
S. Gaito
L. Calabresi
C. Sirtori

January 2010

Some recent clinical reports have suggested that paradoxical decreases in high-density lipoprotein c...

Correlation between plasma levels of fenofibrate and lipoprotein changes in hyperlipidaemic patients

C.R. Sirtori
G. Montanari
G. Gianfranceschi
M. Sirtori
G. Galli
E. Bosisio

January 1985

Eleven hyperlipidaemic patients received two formulations of fenofibrate (differing in in vitro diss...

Lipoprotein subfraction concentrations and size using NMR after 4 months according to treatment group (VLDL-P; LDL-P; HDL-P; Lipoprotein size).

Ruben N. Eppinga (848156)
Minke H. T. Hartman (848157)
Dirk J. van Veldhuisen (128863)
Chris P. H. Lexis (848158)
Margery A. Connelly (799170)
Erik Lipsic (808163)
Iwan C. C. van der Horst (848159)
Pim van der Harst (65060)
Robin P. F. Dullaart (196402)

January 2016

Data are presented as median (interquartile range). P-values from unpaired—tests. P...

Assessment of fenofibrate-methylation interactions on triglycerides using longitudinal family data

Yu, JC

[[abstract]]Background: Triglyceride (TG) concentrations decrease in response to fenofibrate treatme...

Regulatory Effects of Fenofibrate and Atorvastatin on Lipoprotein A-I and Lipoprotein A-I:A-II Kinetics in the Metabolic Syndrome

Dick C. Chan
Gerald F. Watts
Esther M. M. Ooi
Anthony G. Johnson
P. Hugh
R. Barrett

August 2016

OBJECTIVE — Subjects with the metabolic syndrome have reduced HDL cholesterol con-centration and alt...

High Density Lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy

Yetukuri, Laxman
Huopaniemi, I.
Koivuniemi, Artturi
Maranghi, M.
Hiukka, A.
Nygren, Heli
Kaski, S.
Taskinen, M.-R.
Vattulainen, I.
Jauhiainen, M.
Orešič, Matej

January 2011

In a recent FIELD study the fenofibrate therapy surprisingly failed to achieve significant benefit o...

Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study

Ansquer, Jean-Claude
Corda, Christophe
Le Malicot, Karine
Jessent, Valerie

April 2009

AbstractBackground: Elevated plasma low-density lipoprotein cholesterol (LDL-C) concentrations are h...

High Density Lipoprotein Structural Changes and Drug Response in Lipidomic Profiles following the Long-Term Fenofibrate Therapy in the FIELD Substudy

Laxman Yetukuri
Ilkka Huopaniemi
Artturi Koivuniemi
Marianna Maranghi
Anne Hiukka
Samuel Kaski
Marja-riitta Taskinen
Ilpo Vattulainen
Matti Jauhiainen

August 2016

In a recent FIELD study the fenofibrate therapy surprisingly failed to achieve significant benefit o...

Percent changes after fenofibrate intervention in high TG subgroup versus lipoprotein cluster 3.

Kees van Bochove (158872)
Daniël B. van Schalkwijk (158880)
Laurence D. Parnell (158888)
Chao-Qiang Lai (158896)
José M. Ordovás (5648779)
Albert A. de Graaf (158909)
Ben van Ommen (47414)
Donna K. Arnett (123469)

June 2012

†indicates significantly different with respect to cluster 3 and high TG subgroup, p<0.01.‡<p...

Percent changes after fenofibrate intervention in low HDLc subgroup versus subjects in lipoprotein clusters 2 and 3.

Kees van Bochove (158872)
Daniël B. van Schalkwijk (158880)
Laurence D. Parnell (158888)
Chao-Qiang Lai (158896)
José M. Ordovás (5648779)
Albert A. de Graaf (158909)
Ben van Ommen (47414)
Donna K. Arnett (123469)

June 2012

†indicates significantly different with respect to cluster 2/3 and not low HDL subgroup, p<0.01.<...

Percent changes after fenofibrate intervention, grouped by NMR clustering.

Kees van Bochove (158872)
Daniël B. van Schalkwijk (158880)
Laurence D. Parnell (158888)
Chao-Qiang Lai (158896)
José M. Ordovás (5648779)
Albert A. de Graaf (158909)
Ben van Ommen (47414)
Donna K. Arnett (123469)

June 2012

†indicates significantly different with respect to cluster 1, p<0.01.‡indicates significan...

Clustering by Plasma Lipoprotein profile reveals two distinct subgroups with positive lipid response to Fenofibrate therapy

Bochove, K. van
Schalkwijk, D.B. van
Parnell, L.D.
Lai, C.Q.
Ordovás, J.M.
Graaf, A.A. de
Ommen, B. van
Arnett, D.K.

January 2012

Fibrates lower triglycerides and raise HDL cholesterol in dyslipidemic patients, but show heterogene...

Clustering by Plasma Lipoprotein Profile Reveals Two Distinct Subgroups with Positive Lipid Response to Fenofibrate Therapy

Kees Van Bochove
Daniël B. Van Schalkwijk
Laurence D. Parnell
Chao-qiang Lai

August 2016

Fibrates lower triglycerides and raise HDL cholesterol in dyslipidemic patients, but show heterogene...

Baseline characteristics of subjects in clustering on lipoprotein profile.

Kees van Bochove (158872)
Daniël B. van Schalkwijk (158880)
Laurence D. Parnell (158888)
Chao-Qiang Lai (158896)
José M. Ordovás (5648779)
Albert A. de Graaf (158909)
Ben van Ommen (47414)
Donna K. Arnett (123469)

June 2012

†indicates significantly different with respect to cluster 1, p<0.01.‡indicates significan...

702 Fenofibrate and LDL Metabolic Heterogeneity in Hypercholesterolemia

October 2016

Metabolic heterogeneity in low density lipoprotein (LDL) may be detected by examination of the daily...

Paradoxical decrease in high density lipoprotein cholesterol with fenofibrate : a quite rare phenomenon indeed

G. Mombelli
F. Pazzucconi
A. Bondioli
A. Zanaboni
S. Gaito
L. Calabresi
C. Sirtori

January 2010

Some recent clinical reports have suggested that paradoxical decreases in high-density lipoprotein c...

Correlation between plasma levels of fenofibrate and lipoprotein changes in hyperlipidaemic patients

C.R. Sirtori
G. Montanari
G. Gianfranceschi
M. Sirtori
G. Galli
E. Bosisio

January 1985

Eleven hyperlipidaemic patients received two formulations of fenofibrate (differing in in vitro diss...

Lipoprotein subfraction concentrations and size using NMR after 4 months according to treatment group (VLDL-P; LDL-P; HDL-P; Lipoprotein size).

Ruben N. Eppinga (848156)
Minke H. T. Hartman (848157)
Dirk J. van Veldhuisen (128863)
Chris P. H. Lexis (848158)
Margery A. Connelly (799170)
Erik Lipsic (808163)
Iwan C. C. van der Horst (848159)
Pim van der Harst (65060)
Robin P. F. Dullaart (196402)

January 2016

Data are presented as median (interquartile range). P-values from unpaired—tests. P...

Assessment of fenofibrate-methylation interactions on triglycerides using longitudinal family data

Yu, JC

[[abstract]]Background: Triglyceride (TG) concentrations decrease in response to fenofibrate treatme...

Regulatory Effects of Fenofibrate and Atorvastatin on Lipoprotein A-I and Lipoprotein A-I:A-II Kinetics in the Metabolic Syndrome

Dick C. Chan
Gerald F. Watts
Esther M. M. Ooi
Anthony G. Johnson
P. Hugh
R. Barrett

August 2016

OBJECTIVE — Subjects with the metabolic syndrome have reduced HDL cholesterol con-centration and alt...

High Density Lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy

Yetukuri, Laxman
Huopaniemi, I.
Koivuniemi, Artturi
Maranghi, M.
Hiukka, A.
Nygren, Heli
Kaski, S.
Taskinen, M.-R.
Vattulainen, I.
Jauhiainen, M.
Orešič, Matej

January 2011

In a recent FIELD study the fenofibrate therapy surprisingly failed to achieve significant benefit o...

Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study

Ansquer, Jean-Claude
Corda, Christophe
Le Malicot, Karine
Jessent, Valerie

April 2009

AbstractBackground: Elevated plasma low-density lipoprotein cholesterol (LDL-C) concentrations are h...

High Density Lipoprotein Structural Changes and Drug Response in Lipidomic Profiles following the Long-Term Fenofibrate Therapy in the FIELD Substudy

Laxman Yetukuri
Ilkka Huopaniemi
Artturi Koivuniemi
Marianna Maranghi
Anne Hiukka
Samuel Kaski
Marja-riitta Taskinen
Ilpo Vattulainen
Matti Jauhiainen

August 2016

In a recent FIELD study the fenofibrate therapy surprisingly failed to achieve significant benefit o...

Percent changes after fenofibrate intervention in medium TG subgroup versus lipoprotein cluster 2.

Abstract

Extracted data

Percent changes after fenofibrate intervention in medium TG subgroup versus lipoprotein cluster 2.

Abstract

Extracted data

Related items

Related items